Abeona Therapeutics’ Board of Directors Forms Special Committee to Oversee Operations, Develop Strategic Direction and Leadership Plan
06 oct. 2020 16h01 HE
|
Abeona Therapeutics Inc.
Steven H. Rouhandeh Appointed as Chairman of the Board of Directors Jefferies LLC Retained as Financial Advisor to Assist with the Review of Strategic Options NEW YORK and CLEVELAND, Oct. 06,...
Abeona Therapeutics Announces Leadership and Board Transitions
28 sept. 2020 09h27 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced changes in its executive...
Abeona Therapeutics to Participate in Upcoming Investor Conferences
08 sept. 2020 16h05 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that the Company will...
Abeona Therapeutics and Taysha Gene Therapies Enter into Licensing and Inventory Purchase Agreements for ABO-202, a Clinical Stage, Novel, One-time Gene Therapy for CLN1 Disease
17 août 2020 07h00 HE
|
Abeona Therapeutics Inc.; Taysha Gene Therapies
NEW YORK and CLEVELAND and DALLAS, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, and Taysha Gene Therapies, a...
Abeona Therapeutics gibt Geschäftsergebnisse für das zweite Quartal und Unternehmensneuigkeiten bekannt
11 août 2020 16h46 HE
|
Abeona Therapeutics Inc.
Weitere Patienten in den klinischen Programmen zu RDEB, MPS IIIA und MPS IIIB behandelt Allgemeine Abstimmung mit dem CHMP über Pläne zur EU-Registrierung von ABO-102 für MPS IIIA Daten aus RDEB-...
Abeona Therapeutics annonce ses résultats financiers et mises à jour du deuxième trimestre
11 août 2020 16h46 HE
|
Abeona Therapeutics Inc.
Des patients supplémentaires ont reçu des doses dans le cadre des programmes cliniques sur l'EBDR, le MPS IIIA et le MPS IIIB Alignement général par rapport aux plans d'enregistrement dans l'UE de...
Abeona Therapeutics Reports Second Quarter Financial Results and Business Updates
10 août 2020 16h01 HE
|
Abeona Therapeutics Inc.
Additional patients dosed in RDEB, MPS IIIA and MPS IIIB clinical programs General alignment with CHMP on plans for EU registration of ABO-102 for MPS IIIA Data from RDEB and MPS III programs...
Abeona Therapeutics Announces Two Presentations Related to Its RDEB Clinical Program at the Society for Pediatric Dermatology 45th Annual Meeting
10 juil. 2020 07h30 HE
|
Abeona Therapeutics Inc.
EB-101 treatment of large, chronic wounds is associated with durable healing and pain relief in patients with RDEBLiterature review of 65 studies confirms and expands understanding of substantial...
Abeona Therapeutics Announces Appointment of Michael Amoroso as Chief Commercial Officer
09 juil. 2020 07h30 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, July 09, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Michael...
Abeona Therapeutics Reinitiates Enrollment in EB-101 Pivotal Phase 3 VIITAL™ Study in RDEB after COVID-19 Related Pause and Announces Progress in Patient Enrollment in MPS III Studies
08 juil. 2020 07h30 HE
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, July 08, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced recent updates on its clinical...